08/21/2025
The New York Times characterizes the SetPoint System as offering "new hope to patients incapacitated by rheumatoid arthritis, a chronic condition that afflicts 1.5 million Americans and is often resistant to treatment."
We're so pleased to see this coverage of the FDA approval of the SetPoint System in the New York Times! Read the full feature story to learn more about the life-changing power of neuroimmune modulation:
Individual outcomes vary. Please see important safety information at spm.care/ISI
The device stimulates the vagus nerve, signaling the body to tamp down the inflammation that contributes to the disease.
